Please note: Any medical or genetic information present in this entry is not intended as a diagnosis of your problem, but rather is provided as a helpful guide for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. Information is not necessarily complete. Please see your doctor for diagnosis and treatment.

Please note: DNAtraffic database is the project under construction and information on this page is not finished yet.

lobular carcinoma in situ (LCIS)

It is a condition caused by unusual cells in the lobules of the breast. It is usually not considered cancer, but it can indicate an increased risk of future cancer. Unlike Ductal Carcinoma in Situ (DCIS), LCIS is not associated with calcification, and is typically an incidental finding in a biopsy performed for another reason. It is a non-invasive neoplastic disease of the breast.

Lobular carcinoma in situ (LCIS) is an uncommon condition in which abnormal cells form in the lobules or milk glands in the breast. LCIS isn't cancer. But being diagnosed with LCIS indicates that you have an increased risk of developing breast cancer.
LCIS usually doesn't show up on mammograms. The condition is most often discovered as a result of a biopsy done for another reason, such as a suspicious breast lump or an abnormal mammogram.
Women with LCIS have an increased risk of developing invasive breast cancer in either breast. If you're diagnosed with LCIS, your doctor may recommend increased breast cancer screening and may ask you to consider treatments to reduce your risk of invasive breast cancer.
LCIS may be treated with close clinical follow-up and mammographic screening, tamoxifen, or bilateral prophylactic mastectomy.
A recent research study found that the hormonal therapy tamoxifen can reduce the risk of breast cancer developing in women with LCIS. But, it's still not clear if the benefits of taking it outweigh the possible risks and side effects it can cause. A second research trial, known as IBIS2, is being carried out to see whether another type of hormonal therapy, called anastrozole| (Arimidex®), can also reduce the risk of breast cancer developing in post-menopausal women who have an increased risk. This trial includes women with LCIS. You can ask your doctor if your local breast unit is involved in this trial.  


TYPE: breast cancer

Related patway(s): Fanconi anemia (FA) pathway, mismatch repair (MMR)

DNAtraffic protein(s) related to disease: MLH1


Last modification date: Sept. 19, 2011